|Last Price$9.32||Day Change (%)0.00%|
|Open Price$9.32||Day Change ($)0.00|
|Day Range9.32–9.32||52-Week Range9.13–9.45|
As of Wed 09/28/2016 | USD
Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients
Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients
Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...
UPDATE: The latest scary way Russia is striking out at dissent
Three stocks we think investors should be wary of.